Walt Disney Co. signed a new multiyear deal to make DraftKings Inc. the official betting site and odds provider for its ESPN sports networks, replacing a venture it had with casino operator Penn Entertainment Inc. Starting on Dec. 1, players will be able to access the DraftKings’ sportsbook, daily fantasy contests and other products through the ESPN sites, according to a statement Thursday from the two companies. Most Read from Bloomberg DraftKings will operate a betting tab on the ESPN app and promote ...

Group 1 - The FPA Crescent Fund reported a gain of 5.54% in Q3 2025 and 15.32% over the trailing twelve months, with top five performers contributing 6.65% and bottom five detracting 2.58% from the returns [1] - Citigroup Inc. (NYSE:C) showed a one-month return of 6.02% and a 49.30% increase in value over the last 52 weeks, closing at $101.69 per share with a market capitalization of $181.954 billion on November 5, 2025 [2] - Citigroup Inc. has improved its return on tangible equity (ROTE) compared to industry peers, benefiting from a low starting valuation, operational improvements, and a favorable regulatory environment, leading to strong share-price performance [3] Group 2 - Citigroup Inc. was held by 102 hedge fund portfolios at the end of Q2 2025, an increase from 96 in the previous quarter, indicating growing interest among institutional investors [4] - While Citigroup Inc. is recognized for its investment potential, certain AI stocks are suggested to offer greater upside potential and less downside risk [4] - The article also mentions a focus on undervalued large-cap stocks, including Citigroup Inc., as part of investment strategies [5]

Core Viewpoint - Biomerica, Inc. is expanding its Contract Development and Manufacturing Organization (CDMO) services to meet increasing market demand for advanced medical diagnostic solutions [1][2]. Group 1: Company Overview - Biomerica has over 40 years of experience in assay development, manufacturing, and regulatory compliance, making it a sought-after partner for biotechnology and diagnostic companies [2]. - The company is positioned to capture growing demand for outsourced diagnostic development and production, supported by ISO 13485 certification and an FDA registered cGMP manufacturing facility [5]. Group 2: CDMO Services Expansion - The expansion of CDMO services aims to provide end-to-end support from concept through commercial manufacturing, addressing the needs of both large and small diagnostic organizations [3][5]. - Biomerica's CDMO services include capabilities in lateral flow, point-of-care diagnostics, ELISA tests, and Multiplex ELISA assays, which help partners reduce timelines and ensure high-quality outcomes [4][5]. Group 3: Marketing and Visibility - The company has updated its corporate website to prominently feature its CDMO capabilities, facilitating easier access for potential partners to understand the expanded service offerings [4]. - The updated site includes service descriptions and resources to support collaboration with innovators [4]. Group 4: Comprehensive Capabilities - Biomerica offers a range of services including custom assay development, antibody and reagent services, recombinant antibody development, manufacturing and assembly, and supply chain and technology transfer [7][8]. - These services are designed to enhance the efficiency and scalability of product development for pharmaceutical, biotechnology, and diagnostic companies [8].

Core Insights - Studios revenue increased by 24% year-over-year, driven by the box-office success of films such as Superman and Weapons [1] Revenue Performance - The significant growth in studios revenue can be attributed to successful film releases, indicating a strong performance in the entertainment sector [1] - The box-office success of key films has played a crucial role in this revenue increase, highlighting the importance of blockbuster releases in driving financial results [1]

Group 1 - The FPA Crescent Fund gained 5.54% in Q3 2025 and 15.32% over the trailing twelve months, with top five performers contributing 6.65% and bottom five detracting 2.58% from the returns [1] - International Flavors & Fragrances Inc. (NYSE:IFF) is a key holding in the fund, with a one-month return of 6.40% but a significant decline of 29.64% over the past 52 weeks, closing at $64.00 per share and a market capitalization of $16.39 billion [2][3] Group 2 - IFF is a major producer of ingredients for various industries, including food and beverage, with its products being essential in many household items [3] - The company has faced challenges due to previous management's poor capital allocation and acquisitions, which led to lower margins and increased leverage [3] - A new CEO is focusing on operational excellence and divesting non-core assets, which is expected to reduce leverage and improve margins [3] - Current free cash flow of approximately $4 is projected to increase to $5-6 in a few years, potentially leading to a higher P/E ratio in line with peers [3] - The stock price, currently at $61, has a potential path to double if the company executes its strategy effectively [3]

Core Insights - CarMax has terminated its CEO Bill Nash, who held the position since 2016, indicating a significant leadership change within the company [1] - David McCreight, a board member, has been appointed as the interim president, suggesting a temporary leadership solution while the company seeks a permanent replacement [1] Company Summary - The leadership transition comes as CarMax navigates its operational strategies and market challenges, reflecting potential shifts in company direction [1] - The decision to replace the CEO may impact investor confidence and market perception of CarMax's future performance [1]

Company Update - VSee Health is collaborating with the Philippine Tuberculosis Society and former Vice President Leni Robredo to enhance healthcare delivery in Naga City through digital health innovation, focusing on maternal health and primary care [1][2] - The meeting highlighted significant healthcare challenges in Naga City, including low prenatal check-up rates of 44% compared to the Department of Health's target of 99%, and initiatives like healthcare caravans and PhilHealth's YAKAP project providing financial support for primary care [2] Industry Insights - The Southeast Asia digital health market reached USD 17 billion in 2024 and is projected to grow to USD 38.8 billion by 2033, with the Philippines expected to surpass USD 1 billion by 2027 as governments accelerate digital transformation in healthcare [3] - VSee's AI-driven telehealth platform supports various initiatives, including Project MAMA aimed at reducing maternal and fetal deaths, and collaborations for TB screenings with innovative medtech companies [4] Strategic Goals - VSee Health aims to deepen partnerships that integrate technology, clinical expertise, and public sector leadership to improve population health in the Philippines and Southeast Asia [5]

Group 1 - Ericsson operates in a volatile telecommunications sector, focusing on structure rather than promises [1] - The company has a long-term investment philosophy that emphasizes underfollowed or undervalued companies, as well as established leaders with emerging structural value [1] Group 2 - The article does not provide specific financial data or performance metrics related to Ericsson or the telecommunications industry [2][3]

BREAKING: Futures Mixed Amid Earnings Movers; Elon Musk Pay Vote Due Tesla (TSLA) stock is trading around a buy point with the EV giant's annual shareholder meeting scheduled after the stock market close Thursday. Investors will decide whether to approve CEO Elon Musk's $1 trillion pay deal along with Tesla investment in xAI and several other measures. In the run-up to Thursday's votes. Musk has said the $1 trillion pay proposalâ€| Related news These Are The Best Robinhood Stocks To Buy Or Watch Now 11/05/2 ...

Key Takeaways Ashland's Q4 profit rose to $32M from $16M YoY, though adjusted EPS fell short of estimates.Sales declined 8% year over year to $478M, weighed by divestitures.The company expects full-year fiscal 2026 adjusted EBITDA to be $400-$430 million.Ashland Global Holdings Inc. (ASH) recorded a profit of $32 million or 71 cents per share for the fourth-quarter fiscal 2025 (ended Sept. 30, 2025) compared with a profit of $16 million or 33 cents in the prior-year quarter. Barring one-time items, adjusted ...